PubMed Health⌕ Search
Home/Archive/PubMed

PubMed · 11712398

[Insulin lispro].

A Matsuda
View original source ↗Export metadata ↓

Abstract

The results of the clinical studies of insulin lispro carried out in Japan to confirm the pharmacodynamics, pharmacokinetics, efficacy and safety, which were recently released were summarized in this article. When compared to human regular insulin, single subcutaneous injection to healthy persons showed that insulin lispro was adsorbed and disappeared more rapidly in blood stream and blood lowering action revealed more early. The potency of hypoglycemic action was stronger. Long-term multicenter, randomized, comparative, parallel, open-label study to diabetic patients of both type 1 and type 2 by multiple injection method showed that insulin lispro resulted in the significant improvement of 2 hour-postprandial blood glucose level 12 and 24 weeks after the initiation of treatment. HbA1c level did not change between two groups during the study. Insulin lispro did not give any adverse effects during 48 week-study. These studies support the conclusion that insulin lispro is useful and effective in the treatment of diabetes as a short-acting insulin.

Explore related subjects

Blood GlucoseDiabetes MellitusGlycated HemoglobinHumansHypoglycemic AgentsInjections, SubcutaneousInsulinInsulin LisproMulticenter Studies as TopicPostprandial PeriodRandomized Controlled Trials as TopicJournal ArticleReview

Keep this discovery

Explore connections, maps & timelines

BibTeXRIS

A Matsuda. 2001. [Insulin lispro].. https://pubmed.ncbi.nlm.nih.gov/11712398/

Cite the original work for its findings. Save a collection to share your selection of sources.

KEEP EXPLORING

Related citations

PubMed2003

Bone in the pregnant mother and newborn at birth.

BACKGROUND: Changes in maternal bone during pregnancy may affect fetal bone mineralization. ISSUES: The biphasic changes in maternal bone histology (temporary loss of cancellous bone in early pregnancy restored by term gestation) are consistent with corresponding blood biochemistry changes; increased bone resorption markers in the first trimester, while bone formation markers increased in the last trimester. Postpartum bone mineral density (BMD) by DEXA is increased at cortical bone and decreased at trabecular bone sites compared with prepregnancy values. The mean reduction of spine BMD is 3.5% from prepregnancy to immediate postpartum. Neonatal bone mineral content (BMC) is different by season of birth, low weight relative to gestation, and having a diabetic mother. Lower total body BMC and high bone resorption marker in winter vs. summer-born newborns was related to low vitamin D, indicating alterations of fetal bone metabolism by maternal D deficiency. Lower BMC and decreased bone formation marker in infants born small for gestational age than those born appropriate for gestation may relate to reduced transplacental mineral transfer. Low BMC in infants of diabetic mother was correlated inversely with poor control of maternal diabetes during early pregnancy. CONCLUSIONS: During pregnancy, maternal bone mineral metabolism are changed, and influences on fetal bone mineralization occur in utero.

Blood Glucose↗
PubMed2003

A combination of high concentrations of serum triglyceride and non-high-density-lipoprotein-cholesterol is a risk factor for cardiovascular disease in subjects with abnormal glucose metabolism--The Hoorn Study.

AIMS/HYPOTHESIS: Type 2 diabetes is not only associated with hyperglycaemia, but also with disorders of lipid metabolism. The aim of this study was to investigate the association of triglyceride and non-HDL-cholesterol concentrations with cardiovascular disease in subjects with normal and abnormal glucose metabolism. METHODS: Subjects were 869 men and 948 women aged 50 to 75 who participated in the Hoorn Study, a population-based cohort study that started in 1989. Glucose metabolism was determined by a 75 g OGTT. High fasting triglyceride and non-HDL-cholesterol concentrations were defined as above the median of the study population. RESULTS: After 10 years of follow-up, the age- and sex-adjusted hazard ratios for cardiovascular disease were 1.35 (1.11-1.64) and 1.71 (1.40-2.08) for high triglycerides and high non-HDL-cholesterol, respectively, after mutual adjustment. After stratification for glucose metabolism status, the hazard ratios for cardiovascular disease for non-HDL-cholesterol were 1.70 (1.31-2.21) in normal glucose metabolism and 1.56 (1.12-2.18) in abnormal glucose metabolism. Triglycerides were not a risk factor in subjects with normal glucose metabolism, with a hazard ratio of 0.94 (0.73-1.22), but in subjects with abnormal glucose metabolism, the hazard ratio for cardiovascular disease was 1.54 (1.07-2.22). In subjects with abnormal glucose metabolism, the hazard ratio for the combined presence of high triglycerides and non-HDL-cholesterol was 2.12 (1.35-3.34). CONCLUSION: Our data suggest that in people with abnormal glucose metabolism, but not in those with normal glucose metabolism, high triglyceride concentration could be associated with the risk of cardiovascular disease, particularly in people with high non-HDL-cholesterol.

Blood Glucose↗